Insmed reported $113.82M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
DBV Technologies DBVT:US 30.43M 4.4M
Acelrx Pharmaceuticals ACRX:US $ 17.69M 0.66M
Alimera Sciences ALIM:US $ 25.43M 8.43M
Biomarin Pharmaceutical BMRN:US $ 464.73M 25.69M
Cytokinetics CYTK:US $ 66.84M 0M
Dynavax Technologies DVAX:US $ 345.2M 121M
Gilead Sciences GILD:US $ 9220M 662M
Heron Therapeutics HRTX:US $ 109.5M 16.5M
Insmed INSM:US $ 113.82M 11.43M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Novartis NVS:US $ 27646M 2161M
Ophthotech OPHT:US $ 26.48M 7.31M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Sarepta Therapeutics SRPT:US $ 545.57M 90.6M
Seattle Genetics SGEN:US $ 608.52M 77.23M
Ultragenyx Pharmaceutical RARE:US $ 220.64M 53.4M
Vertex Pharmaceuticals VRTX:US $ 2556.2M 376M